220 related articles for article (PubMed ID: 14518094)
1. [Cytoprotective effects of amifostine in the treatment of tumors].
Burkon P; Petýrek P; Spurný V
Vnitr Lek; 2003 Aug; 49(8):673-8. PubMed ID: 14518094
[TBL] [Abstract][Full Text] [Related]
2. [Cytoprotection with amifostine in radiotherapy or radio-chemotherapy of head and neck tumors].
Altmann S; Hoffmanns H
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():30-3. PubMed ID: 10584138
[TBL] [Abstract][Full Text] [Related]
3. Radioprotective effects of amifostine.
Wasserman T
Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
[TBL] [Abstract][Full Text] [Related]
4. [Renal protection with amifostine during intraoperative peritoneal chemohyperthermia (IPCH) with cisplatin (CDDP) for peritoneal carcinosis. Phase 1 study].
Vaira M; Barone R; Aghemo B; Mioli PR; De Simone M
Minerva Med; 2001 Aug; 92(4):207-11. PubMed ID: 11535965
[TBL] [Abstract][Full Text] [Related]
5. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia R
Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
[TBL] [Abstract][Full Text] [Related]
6. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
7. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
[TBL] [Abstract][Full Text] [Related]
8. A new administration schedule for amifostine as a radioprotector in cancer therapy.
Wagner W; Radmard A; Schönekaes KG
Anticancer Res; 1999; 19(3B):2281-3. PubMed ID: 10472344
[TBL] [Abstract][Full Text] [Related]
9. [New data on cytoprotection in radiotherapy].
Sauer R; Strnad V
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():1. PubMed ID: 10584131
[No Abstract] [Full Text] [Related]
10. [Radioprotective effects on head and neck tumors of amifostine--a broad-spectrum cytoprotection].
Huang R; Yu H; Kuang A
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2002 Dec; 19(4):708-11. PubMed ID: 12561384
[TBL] [Abstract][Full Text] [Related]
11. Impact on cytoprotective efficacy of intermediate interval between amifostine administration and radiotherapy: a retrospective analysis.
Kouloulias VE; Kouvaris JR; Kokakis JD; Kostakopoulos A; Mallas E; Metafa A; Vlahos LJ
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1148-56. PubMed ID: 15234050
[TBL] [Abstract][Full Text] [Related]
12. Individualization of the subcutaneous amifostine dose during hypofractionated / accelerated radiotherapy.
Koukourakis MI; Abatzoglou I; Sivridis L; Tsarkatsi M; Delidou H
Anticancer Res; 2006; 26(3B):2437-43. PubMed ID: 16821629
[TBL] [Abstract][Full Text] [Related]
13. The potential influence of cell protectors for dose escalation in cancer therapy: an analysis of amifostine.
McCumber LM
Med Dosim; 2004; 29(2):139-43. PubMed ID: 15191764
[TBL] [Abstract][Full Text] [Related]
14. Clinical applications of radioprotectors.
Werner-Wasik M
Expert Rev Anticancer Ther; 2001 Aug; 1(2):309-16. PubMed ID: 12113036
[TBL] [Abstract][Full Text] [Related]
15. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Capizzi RL; Oster W
Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
[TBL] [Abstract][Full Text] [Related]
16. Amifostine: drug profile and nursing implications of the first pancytoprotectant.
Viele CS; Holmes BC
Oncol Nurs Forum; 1998 Apr; 25(3):515-23. PubMed ID: 9568606
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
[TBL] [Abstract][Full Text] [Related]
19. Cytoprotective effects of amifostine in the treatment of childhood malignancies.
Cetingül N; Midyat L; Kantar M; Demirağ B; Aksoylar S; Kansoy S
Pediatr Blood Cancer; 2009 Jul; 52(7):829-33. PubMed ID: 19214974
[TBL] [Abstract][Full Text] [Related]
20. Antimetastatic effectiveness of amifostine therapy following surgical removal of Sa-NH tumors in mice.
Grdina DJ; Kataoka Y; Murley JS; Swedberg K; Lee JY; Hunter N; Weichselbaum RR; Milas L
Semin Oncol; 2002 Dec; 29(6 Suppl 19):22-8. PubMed ID: 12577239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
